TWILIGHT-HF Subgroup Analysis Score

Clinical calculation support · Verify results before clinical use

Important clinical limitation: This six-item point count is an unvalidated, locally constructed teaching aid—not an official TWILIGHT score, not a validated heart-failure subgroup model, and not a tool for choosing antiplatelet therapy. The score bands below are arbitrary and have no established relationship to event probabilities.

Patient characteristics

Select or enter the characteristics that apply.

0Points
01

One exploratory point for age 65 years or older.

Adults only. Enter a whole number from 18 to 120.

Sex
02
Sex

Select the recorded sex.

Clinical presentation
03
Clinical presentation

Presentation at the index PCI.

Diabetes mellitus
04
Diabetes mellitus

History of diabetes mellitus.

Chronic kidney disease
05
Chronic kidney disease

Defined here as eGFR <60 mL/min/1.73 m².

Anemia
06
Anemia

Known low hemoglobin / documented anemia.

0Points
Exploratory count only
Not yet assessed
Enter age and select each characteristic to calculate the point count.
How to interpret this result

The count is not a validated risk prediction. It must not be used to estimate an individual's bleeding risk, ischemic risk, or treatment benefit.

TWILIGHT trial reference outcomes

These are published overall-trial rates, shown as context only. They are not adjusted according to this point count.

Ticagrelor monotherapy4.0%BARC type 2, 3, or 5 bleeding
Ticagrelor + aspirin7.1%BARC type 2, 3, or 5 bleeding

Published TWILIGHT estimates at 12 months after randomization among selected patients who completed 3 months of ticagrelor plus aspirin without a major ischemic or bleeding event. These group-level trial estimates are not individual predictions.

About this exploratory tool

This page adds one point for each of six selected characteristics: age 65 years or older, female sex, ACS presentation, diabetes, CKD, and anemia. The simple count was constructed for educational illustration; it is not a score developed or validated by the TWILIGHT investigators.

Point-count rules

CharacteristicExploratory rulePoints
Age≥65 years+1
SexFemale+1
PresentationACS+1
DiabetesPresent+1
CKDeGFR <60 mL/min/1.73 m²+1
AnemiaKnown / documented+1

Count bands (arbitrary, not clinical risk strata)

CountDisplay bandClinical meaning
0–1Lower item countNo validated risk interpretation
2–3Middle item countNo validated risk interpretation
4–6Higher item countNo validated risk interpretation

Clinical context

TWILIGHT randomized selected high-risk patients who had undergone PCI and completed 3 months of ticagrelor plus aspirin without a major ischemic or bleeding event. The trial compared continued ticagrelor with aspirin versus ticagrelor with placebo for the following 12 months. It did not establish the six-variable point count on this page as a prognostic score.

Evidence and references

Mehran R, Baber U, Sharma SK, et al.Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine. 2019;381:2032–2042. DOI: 10.1056/NEJMoa1908419. Primary trial for the overall outcome rates displayed above.
TWILIGHT trial recordClinicalTrials.gov identifier: NCT02270242. Official study record.
TWILIGHT subgroup analysis: sex differencesPrespecified secondary analysis of treatment effects by sex. JAMA Cardiology. 2021. PubMed: PMID 33991416. This analysis does not validate the point count used on this page.
Verification noteNo primary publication validating this exact six-item score or a score named “TWILIGHT-HF Subgroup Analysis Score” was identified in the sources reviewed for this redesign. The existence of a specific HF subgroup model remains unverified.
Clinical disclaimer: This is an educational, exploratory point count only. It is not validated for prognostic assessment, bleeding-risk estimation, ischemic-risk estimation, or selection of antiplatelet treatment. Do not use it to stop aspirin, prescribe ticagrelor, or modify antithrombotic therapy. Treatment decisions should be based on the patient's clinical context, bleeding and ischemic risk, applicable guidelines, and clinician judgment.